GPR40‐induced insulin secretion by the novel agonist TAK‐875: first clinical findings in patients with type 2 diabetes
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Aim: Free fatty acids act as signalling molecules for modulating insulin secretion, and their insulinotropic effects are glucose‐dependent and mediated through G protein‐coupled receptor 40 (GPR40). This mechanism is a potential target for new treatments for managing diabetes. In this study, we present the first clinical data for TAK‐875, a novel highly selective, orally bioavailable GPR40 agonist, in Japanese patients with type 2 diabetes insufficiently controlled by diet or exercise therapy. Methods: This was an exploratory phase II, multicentre, randomized, double‐blind, parallel group study comparing the efficacy and tolerability of TAK‐875 100 and 400 mg, and placebo, all administered once daily for 2 weeks. Results: After 2 weeks of treatment, TAK‐875 produced marked glucose lowering effects in a 75 g oral glucose tolerance test (OGTT) as evidenced by mean ± SE intergroup differences in plasma glucose AUC 0–3 h of −12.98 ± 1.48 (p < 0.0001) and −8.12 ± 1.49 mmol·h/l (p < 0.0001), for TAK‐875 400 mg vs. placebo and TAK‐875 100 mg vs. placebo, respectively, and 2 h plasma glucose [−4.95 ± 0.71 (p < 0.0001) and −3.21 ± 0.71 mmol/l (p < 0.0001), respectively]. This was accompanied by a significant increase in insulin AUC 0–3 h [34.68 ± 12.16 (p < 0.01) and 31.49 ± 12.20 (p < 0 · 05) µIU·h/ml, respectively]. Improvement in glycaemic profile was mirrored by a significant change in fasting plasma glucose [−2.37 ± 0·27 (p < 0.0001) and −1.88 ± 0.27 mmol/l (p < 0.0001), respectively]. No cases of hypoglycaemia were observed despite the significant reduction in plasma glucose. Conclusions: These exploratory findings provide evidence of the glucose‐dependent insulinotropic potential of the GPR40 agonist TAK‐875, and the promising clinical changes support future longer term clinical investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 1×
“like peptide-1 (GLP-1), have been developed [5,6].”
Free fatty acids regulate insulin secretion from pancreatic β cells through GPR40
Itoh, Y., Kawamata, Y., Harada, M., Kobayashi, M., Fujii, R., Fukusumi, S., Ogi, K., Hosoya, M., Tanaka, Y., Uejima, H., et al. (2003) · Nature · doi:10.1038/nature01478 · Cited by 1,538 · cited 1×
“G protein-coupled receptor 40 [GPR40, also known as free fatty acid receptor 1 (FFAR1)] [8] is highly expressed in pancreatic β-cells and activated by long-chain free fatty acids (FFAs) [9,10].”
BackgroundSeino, Y., Nanjo, K., Tajima, N., Kadowaki, T., Kashiwagi, A., Araki, E., Ito, C., Inagaki, N., Iwamoto, Y., Kasuga, M., et al. (2010) · Diabetology International · doi:10.1007/s13340-010-0006-7 · Cited by 614
Edfalk, S., Steneberg, P., & Edlund, H. (2008) · Diabetes · doi:10.2337/db08-0307 · Cited by 587 · cited 1×
“In this regard, it should be noted that GPR40 modulates insulin secretion from β-cells not only directly, but also indirectly via regulation of incretin secretion [25].”
BackgroundThe Influence of GLP-1 on Glucose-Stimulated Insulin Secretion
Kjems, L. L., Holst, J. J., Vølund, A., & Madsbad, S. (2003) · Diabetes · doi:10.2337/diabetes.52.2.380 · Cited by 582 · cited 1×
“like peptide-1 (GLP-1), have been developed [5,6].”
Fujiwara, K., Maekawa, F., & Yada, T. (2005) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00035.2005 · Cited by 253
Role of GPR40 in fatty acid action on the β cell line INS-1E
Shapiro, H., Shachar, S., Sekler, I., Hershfinkel, M., & Walker, M. D. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.07.042 · Cited by 220 · cited 1×
“It has been postulated that FFAs interact with GPR40 with a resultant increase in cytosolic Ca2+ via phospholipase C and L-type Ca2+ channels [15,16].”
Background
Cited by
Complex Pharmacology of Free Fatty Acid Receptors
Milligan, G., Shimpukade, B., Ulven, T., & Hudson, B. D. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00056 · Cited by 267
Yamada, H., Yoshida, M., Ito, K., Dezaki, K., Yada, T., Ishikawa, S.-E., & Kakei, M. (2016) · Scientific Reports · doi:10.1038/srep25912 · Cited by 81
Ceja-Galicia, Z. A., Cespedes-Acuña, C. L. A., & El-Hafidi, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020788 · Cited by 61
“…been found to increase insulin secretion and improve glucose tolerance without causing hypoglycemia and other serious side effects in patients with type II diabetes for the first time, making it a potential new treatment for type II diabetes, as reported by Leifke et al. and Araki et al. [97,98].”
GPR40: A therapeutic target for mediating insulin secretion
FENG, X.-T., LENG, J., XIE, Z., LI, S.-L., ZHAO, W., & TANG, Q.-L. (2012) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2012.1142 · Cited by 54
Metadata
- Authors
- Araki, T., Hirayama, M., Hiroi, S., & Kaku, K.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2011-12-22
- Volume
- 14
- Issue
- 3
- Pages
- 271-278
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W1985487963
- Cited by
- 96
- References
- 7
- FWCI
- 9.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: GPR40‐induced insulin secretion by the novel agonist TAK‐875: first clinical findings in patients with type 2 diabetes. https://app.cochat.ai/papers/10.1111/j.1463-1326.2011.01525.x
- The paper
- Araki, T., Hirayama, M., Hiroi, S., & Kaku, K. (2012). GPR40‐induced insulin secretion by the novel agonist TAK‐875: first clinical findings in patients with type 2 diabetes. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2011.01525.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.